Search
Cytochrome c1, heme protein, mitochondrial
go.drugbank.com/bio_entities/BE0003854TargetHumansThe respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Cytochrome c1 is a catalytic core subunit containing a c-type heme. It transfers electrons from the [2Fe-2S] iron-sulfur cluster of the Rieske protein to cytochrome c
Synonyms: Complex III subunit 4, Complex III subunit IVCytochrome b
go.drugbank.com/bio_entities/BE0000938TargetHumansComponent of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex) that is part of the mitochondrial respiratory chain. … The b-c1 complex mediates electron transfer from ubiquinol to cytochrome c. Contributes to the generation of a proton gradient across the mitochondrial membrane that is then used for ATP synthesis
Synonyms: Complex III subunit 3, Complex III subunit IIIEftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing
Grapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approved[L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]
Pseudoazurin
go.drugbank.com/bio_entities/BE0001952TargetAlcaligenes faecalisThis soluble electron transfer copper protein is required for the inactivation of copper-containing nitrite reductase in the presence of oxygen.
Synonyms: Blue copper proteinFunction: copper ion bindingEtravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalOn March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. … In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
Tumor susceptibility gene 101 protein
go.drugbank.com/bio_entities/BE0019070TargetHumansComponent of the ESCRT-I complex, a regulator of vesicular trafficking process. … Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation.
Synonyms: ESCRT-I complex subunit TSG101Glofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational[L45698,A258488] Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20